Aller au contenu

Castration-resistant metastatic prostate cancer and first-line treatments

21 mai 2024

Castration-resistant metastatic prostate cancer and first-line treatments

Prostate cancer is the most common cancer in men over 50. Currently, the overall survival of a patient with castration-resistant metastatic prostate cancer is estimated at 36 months.Current first-line therapeutic approaches to this cancer include antiandrogens with abiraterone and chemotherapy with docetaxel and cabazitaxel.The study by Duojie Zhang et al examined these first-line therapeutic stra

Prostate cancer is the most common cancer in men over 50. Currently, the overall survival of a patient with castration-resistant metastatic prostate cancer is estimated at 36 months.

Current first-line therapeutic approaches to this cancer include antiandrogens with abiraterone and chemotherapy with docetaxel and cabazitaxel.

The study by Duojie Zhang et al examined these first-line therapeutic strategies through a network meta-analysis. The main objective of this study was to assess the relative efficacy and safety of these therapeutic strategies.

Efficacy was compared in terms of overall survival and incidence of serious adverse events.

Results showed that docetaxel+prednisone and cabazitaxel+prednisone significantly improved overall survival, while abiraterone did not.

The combination of cabazitaxel + prednisone was recommended as the primary choice for first-line treatment of metastatic castration-resistant prostate cancer, due to its favorable safety profile and comparable efficacy at higher doses.

This study also highlighted the importance of considering the molecular and genetic characteristics of tumors to optimize patient outcomes.


Sign in to read the rest

Reserved for healthcare professionals, free registration.

Scientific reference

Zhang D, Weng H, Zhu Z, Gong W, Ma Y. Evaluating first-line therapeutic strategies for metastatic castration-resistant prostate cancer: a comprehensive network meta-analysis and systematic review. Front Oncol. 2024 Apr 15;14:1378993. doi: 10.3389/fonc.202

Voir la source

Autres articles récents

Does Nicotinamide Really Prevent Skin Cancer?

Does Nicotinamide Really Prevent Skin Cancer?

1 juillet 2026

Exercising in Extreme Heat: How Can Performance Be Preserved While Reducing Health Risks?

Exercising in Extreme Heat: How Can Performance Be Preserved While Reducing Health Risks?

29 juin 2026

Oropouche Virus: A New Threat to Monitor During Pregnancy?

Oropouche Virus: A New Threat to Monitor During Pregnancy?

26 juin 2026

Toute la revue de presse
Castration-resistant metastatic prostate cancer… - MEDFLIXS